Indications:
Replacement therapy in adults, children, and adolescents (0–18 years) in:
•Primary immunodeficiency syndromes (PID) with impaired antibody production
•Secondary immunodeficiencies (SID) in patients who suffer from severe or recurrent infections, ineffective antimicrobial treatment and either proven specific antibody failure (PSAF)* or serum IgG level of 4g/L
* PSAF= failure to mount at least a 2-fold rise in IgG antibody titre to pneumococcal polysaccharide and polypeptide antigen vaccines
Immunomodulation in adults, children and adolescents (0–18 years) in:
•Primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count
•Guillain Barré syndrome
•Kawasaki disease (in conjunction with acetylsalicylic acid; see “Dosage and Administration”)
|